Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.

Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MB, Tipton KF, Marco-Contelles J.

Front Neurosci. 2016 May 25;10:205. doi: 10.3389/fnins.2016.00205. Review.

2.

Curcumin: a natural substance with potential efficacy in Alzheimer's disease.

Potter PE.

J Exp Pharmacol. 2013 May 2;5:23-31. doi: 10.2147/JEP.S26803. Review.

3.

Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology.

Stratmann K, Heinsen H, Korf HW, Del Turco D, Ghebremedhin E, Seidel K, Bouzrou M, Grinberg LT, Bohl J, Wharton SB, den Dunnen W, Rüb U.

Brain Pathol. 2016 May;26(3):371-86. doi: 10.1111/bpa.12289.

PMID:
26193084
4.

Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.

Miller N, Feng Z, Edens BM, Yang B, Shi H, Sze CC, Hong BT, Su SC, Cantu JA, Topczewski J, Crawford TO, Ko CP, Sumner CJ, Ma L, Ma YC.

J Neurosci. 2015 Apr 15;35(15):6038-50. doi: 10.1523/JNEUROSCI.3716-14.2015.

5.

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB.

Mov Disord. 2015 Jun;30(7):936-44. doi: 10.1002/mds.26172.

6.

Synapse assembly and neurodevelopmental disorders.

Washbourne P.

Neuropsychopharmacology. 2015 Jan;40(1):4-15. doi: 10.1038/npp.2014.163. Review.

7.

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.

Walls KC, Ager RR, Vasilevko V, Cheng D, Medeiros R, LaFerla FM.

Neurosci Lett. 2014 Jul 11;575:96-100. doi: 10.1016/j.neulet.2014.05.047.

8.

Brain site-specific proteome changes in aging-related dementia.

Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K.

Exp Mol Med. 2013 Sep 6;45:e39. doi: 10.1038/emm.2013.76.

9.

The genetic variation of SORCS1 is associated with late-onset Alzheimer's disease in Chinese Han population.

Xu W, Xu J, Wang Y, Tang H, Deng Y, Ren R, Wang G, Niu W, Ma J, Wu Y, Zheng J, Chen S, Ding J.

PLoS One. 2013 May 20;8(5):e63621. doi: 10.1371/journal.pone.0063621.

10.

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x. Review.

11.

Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Heuer E, Rosen RF, Cintron A, Walker LC.

Curr Pharm Des. 2012;18(8):1159-69. Review.

12.

Alzheimer's disease pathologic cascades: who comes first, what drives what.

Swerdlow RH.

Neurotox Res. 2012 Oct;22(3):182-94. doi: 10.1007/s12640-011-9272-9. Review.

13.

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M.

J Biol Chem. 2011 Sep 30;286(39):34457-67. doi: 10.1074/jbc.M111.229633.

14.

Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE.

Neurobiol Aging. 2011 Mar;32(3):556.e13-23. doi: 10.1016/j.neurobiolaging.2010.10.020.

15.

Recent advances in the development of immunotherapies for tauopathies.

Ubhi K, Masliah E.

Exp Neurol. 2011 Aug;230(2):157-61. doi: 10.1016/j.expneurol.2010.10.007.

16.

Cardiovascular dementia - a different perspective.

Kumari U, Heese K.

Open Biochem J. 2010 Mar 26;4:29-52. doi: 10.2174/1874091X01004010029.

17.

Prion-like transmission of protein aggregates in neurodegenerative diseases.

Brundin P, Melki R, Kopito R.

Nat Rev Mol Cell Biol. 2010 Apr;11(4):301-7. doi: 10.1038/nrm2873. Review.

18.

Cerebral amyloidosis: amyloid subunits, mutants and phenotypes.

Rostagno A, Holton JL, Lashley T, Revesz T, Ghiso J.

Cell Mol Life Sci. 2010 Feb;67(4):581-600. doi: 10.1007/s00018-009-0182-4. Review.

19.

PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease.

Morel M, Couturier J, Lafay-Chebassier C, Paccalin M, Page G.

J Cell Mol Med. 2009 Aug;13(8A):1476-88. doi: 10.1111/j.1582-4934.2009.00849.x. Review.

20.

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106.

Items per page

Supplemental Content

Support Center